Skip to main content


  • New production facility will significantly increase production capacity of RUCONEST®
  • Product manufactured at the new facility during the approval process is now available for distribution within the EU


As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce the approval of our new facility, which will enable us to significantly increase production capacity for supply to patients in the EU

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline